Morphine-like discriminative stimulus effects of buprenorphine and demethoxybuprenorphine in rats: quantitative antagonism by naloxone

HE Shannon, EJ Cone and CW Gorodetzky

The interactions between the opioid antagonist naloxone and the opioids morphine, buprenorphine and demethoxybuprenorphine ( DMB ), an acid- catalyzed rearrangement product of buprenorphine, were evaluated quantitatively in rats trained to discriminate between saline and 3.0 mg/kg of morphine using a two-choice, shock avoidance procedure. Dose- effect curves for each of the three agonists were determined alone and in the presence of varying doses of naloxone (0.01-1.0 mg/kg). Buprenorphine and DMB produced dose-related increases in morphine- appropriate responding which plateaued over at least a 30-fold dose- range for each drug. On a molar basis, buprenorphine was approximately 140 times and DMB approximately 45 times more potent than morphine. Naloxone produced parallel shifts in the dose-effect curves for morphine, buprenorphine and DMB . Schild plots derived from the relative shifts in the dose-effect curves yielded regression lines with slopes which were not significantly different from -1, consistent with naloxone acting as a competitive antagonist of each of the three opioids. The apparent pA2 values for naloxone were 7.85 +/- 0.36 against morphine, 7.48 +/- 0.16 against buprenorphine and 7.17 +/- 0.27 against DMB . Because the 95% CLs overlapped for morphine and buprenorphine, but not for morphine and DMB , these results are consistent with the interpretation that naloxone is acting at the same receptor in antagonizing morphine and buprenorphine but naloxone may be acting in a more complex manner in antagonizing DMB . The effectiveness of naloxone in antagonizing equieffective doses of morphine (3.0 mg/kg), buprenorphine (0.03 mg/kg) and DMB (0.1 mg/kg) were also evaluated when naloxone was administered either 0 or 30 min after the agonist.(ABSTRACT TRUNCATED AT 250 WORDS)

Volume 229, Issue 3, pp. 768-774, 06/01/1984
Copyright © 1984 by American Society for Pharmacology and Experimental Therapeutics

This article has been cited by other articles:

				C. A. Paronis and J. Bergman Apparent pA2 Values of Benzodiazepine Antagonists and Partial Agonists in Monkeys J. Pharmacol. Exp. Ther., September 1, 1999; 290(3): 1222 - 1229. [Abstract] [Full Text]

				H. R. Garner, T. F. Burke, C. D. Lawhorn, J. M. Stoner, and W. D. Wessinger Butorphanol-Mediated Antinociception in Mice: Partial Agonist Effects and Mu Receptor Involvement, J. Pharmacol. Exp. Ther., September 1, 1997; 282(3): 1253 - 1261. [Abstract] [Full Text]

				M. R. Brandt, S. R. Cabansag, and C. P. France Discriminative Stimulus Effects of l-alpha -Acetylmethadol (LAAM), Buprenorphine and Methadone in Morphine-Treated Rhesus Monkeys J. Pharmacol. Exp. Ther., August 1, 1997; 282(2): 574 - 584. [Abstract] [Full Text]